Left ventricular hypertrophy is a leading risk factor for cardiovascular morbidity and mortality.
Although reverse ventricular remodelling was long thought to be irreversible, evidence from …

Background The angiotensin‐receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was
shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of …

Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …

Importance In patients with heart failure and reduced ejection fraction (HFrEF), treatment
with sacubitril-valsartan reduces N-terminal pro–b-type natriuretic peptide (NT-proBNP) …

Background: The morbidity and mortality of patients with functional mitral regurgitation (MR)
remain high, but no pharmacological therapy has been proven effective. The hypothesis of …

Arrhythmogenic cardiomyopathy is a genetic disorder characterized by the risk of life-
threatening arrhythmias, myocardial dysfunction and fibrofatty replacement of myocardial …

(AHA) scientific statement “Treatment of Hypertension in the Prevention and Management of
Ischemic Heart Disease: A Scientific Statement From the American Heart Association …

Ventricular remodeling, first described in animal models of left ventricular (LV) stress and
injury, occurs progressively in untreated patients after large myocardial infarction and in …

Cardiac remodeling is generally accepted as a determinant of the clinical course of heart
failure (HF). Defined as genome expression resulting in molecular, cellular and interstitial …

It is now becoming apparent that dynamic changes occur within the interstitium that directly
contribute to adverse myocardial remodeling following myocardial infarction (MI), with …